Efgartigimod versus intravenous immunoglobulin for antibody-positive autoimmune encephalitis: a retrospective study

Objective To compare the efficacy and safety of efgartigimod and intravenous immunoglobulin (IVIG) in patients with antibody-positive autoimmune encephalitis (AE). Methods This retrospective study included 31 patients with AE, all of whom were antibody-positive, treated between May 2022 and April 2026, with 12 the median number of administrations was 2 (range, 1–6) and 19 in the IVIG group. Short-term outcomes included time to symptom improvement, length of hospital stay, modified Rankin Scale (mRS) score at 3 months, and reduction in mRS score from baseline to 3 months. Longer-term mRS outcomes at 6 months, 12 months, and the last follow-up were exploratory and were analyzed using available assessments. Relapse and adverse events were also compared between the two groups. Results Baseline characteristics were comparable between the two groups. No significant between-group differences were observed in time to symptom improvement, length of hospital stay, 3-month mRS score, or reduction in mRS score from baseline to 3 months (all P > 0.05). In exploratory analyses, mRS scores were numerically lower in the efgartigimod group at 6 months (0.5 vs. 1.0, P = 0.012) and 12 months (0.0 vs. 1.0, P = 0.004), and the distribution of mRS scores at the last follow-up also differed between the groups (P = 0.019); however, these analyses were based on very few patients, and a higher proportion of patients in the efgartigimod group received sequential immunotherapy. These differences therefore cannot be attributed to efgartigimod itself or regarded as evidence of superior long-term efficacy. Relapse rates (16.7% vs. 0%, P = 0.142) and adverse-event rates (16.7% vs. 10.5%, P = 0.630) did not differ significantly between the groups. Conclusion Efgartigimod appears clinically feasible for antibody-positive AE, with short-term efficacy and safety comparable to those of IVIG. Although exploratory analyses showed numerically lower mRS scores in the efgartigimod group at 6 and 12 months, these findings were based on very few patients and were confounded by the imbalance in sequential immunotherapy; they therefore do not demonstrate superior long-term efficacy. These findings require confirmation in prospective controlled studies.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-11-13
DOI
https://doi.org/10.3389/fimmu.2026.1952036
Primary Topic
Autoimmune Neurological Disorders and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Efgartigimod versus intravenous immunoglobulin for antibody-positive autoimmune encephalitis: a retrospective study

Xufeng Wang, Qingcheng Huang, Min Deng, Tao Li
4 links
Frontiers in Immunology
Autoimmune Neurological Disorders and Treatments
article

Efgartigimod versus intravenous immunoglobulin for antibody-positive autoimmune encephalitis: a retrospective study

Xufeng Wang, Qingcheng Huang, Min Deng, Tao Li
article en

Abstract

Objective To compare the efficacy and safety of efgartigimod and intravenous immunoglobulin (IVIG) in patients with antibody-positive autoimmune encephalitis (AE). Methods This retrospective study included 31 patients with AE, all of whom were antibody-positive, treated between May 2022 and April 2026, with 12 the median number of administrations was 2 (range, 1–6) and 19 in the IVIG group. Short-term outcomes included time to symptom improvement, length of hospital stay, modified Rankin Scale (mRS) score at 3 months, and reduction in mRS score from baseline to 3 months. Longer-term mRS outcomes at 6 months, 12 months, and the last follow-up were exploratory and were analyzed using available assessments. Relapse and adverse events were also compared between the two groups. Results Baseline characteristics were comparable between the two groups. No significant between-group differences were observed in time to symptom improvement, length of hospital stay, 3-month mRS score, or reduction in mRS score from baseline to 3 months (all P > 0.05). In exploratory analyses, mRS scores were numerically lower in the efgartigimod group at 6 months (0.5 vs. 1.0, P = 0.012) and 12 months (0.0 vs. 1.0, P = 0.004), and the distribution of mRS scores at the last follow-up also differed between the groups (P = 0.019); however, these analyses were based on very few patients, and a higher proportion of patients in the efgartigimod group received sequential immunotherapy. These differences therefore cannot be attributed to efgartigimod itself or regarded as evidence of superior long-term efficacy. Relapse rates (16.7% vs. 0%, P = 0.142) and adverse-event rates (16.7% vs. 10.5%, P = 0.630) did not differ significantly between the groups. Conclusion Efgartigimod appears clinically feasible for antibody-positive AE, with short-term efficacy and safety comparable to those of IVIG. Although exploratory analyses showed numerically lower mRS scores in the efgartigimod group at 6 and 12 months, these findings were based on very few patients and were confounded by the imbalance in sequential immunotherapy; they therefore do not demonstrate superior long-term efficacy. These findings require confirmation in prospective controlled studies.

Frontiers in ImmunologyVol. 17
Hubei Provincial Hospital of Traditional Chinese Medicine (CN), Renmin Hospital of Wuhan University (CN)
Good health and well-being
Autoimmune Neurological Disorders and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon